ResMed Shares Approach Highs on Strong Start to Year

ResMed shares (ASX: RMD) delivered gains of more than 47% through 2024, and seem intent on challenging the 52 week highs of $39.13 after breaking $38 in today’s session. Though we are only a few sessions into 2025, RMD has continued in similar vein, adding 2.60% so far. The company is a prime figure in…

weekly share tips

18 Share Tips – 15th July 2024

Christopher Watt, Bell Potter Securities    BUY RECOMMENDATIONS   BUY – Technology One (TNE)  This software-as-a-service provider is poised for significant growth given consistent annual profit before tax increases in the past few years, which are projected to continue. Revenue from ordinary activities was up 20 per cent for the half year ending March 31,…

ResMed Inc (ASX: RMD)

  Company Information   ResMed Inc (ASX: RMD) RMD:NYQ, also known as Resmed Inc., produces medical devices and software for the healthcare market. ResMed has recently completed two acquisition deals. On September 29, 2023, they finalized the purchase of KC Machine LLC, acquiring a 44.51% stake in the company at a transaction value of $2.60…

Analyst Remains Bullish on ResMed (ASX: RMD)

ResMed is one of the largest manufacturers of devices for treating respiratory disorders in the world. FY 2023 financial results were solid, but investors were disappointed with reported gross margins. The share price is now trading at prices not seen since early 2020, accelerated by growing concerns that obesity drugs could impact ResMed because many…

Is it time to Buy ResMed Inc. (ASX: RMD)?

ResMed is a global leader in respiratory care devices Except for FY 2016, the company has paid dividends over the last decade ResMed has increased revenues in each of the previous four fiscal years ResMed makes respiratory care hardware and cloud-supported software with a significant focus on sleep apnoea and chronic obstructive pulmonary issues. The…

ResMed Returning to Form

ResMed Returning to Form

After a solid financial performance during the onset of COVID, the ResMed share price began a modest decline. ResMed has opened a new revenue stream, expanding into digital health software. The company operates in a market with substantial growth prospects due to an ageing population, obesity, and the number of undiagnosed sleep apnea patients. ResMed…

Best Resources & Offers